Loading…
Loading…
MNMD (Mind Medicine (MindMed) Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
MNMD does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MNMD and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MNMD and 80,000+ other tickers.
See exactly how MNMD's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MNMD and 80,000+ other tickers.
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for…
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 15,054,621 shares, an increase of 19.4% from the December 15th total of 12,612,667 shares. Currently, 15.6% of the company's stock are sold short. Based on
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) CEO Robert Barrow sold 25,791 shares of the business's stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the sale, the chief executive officer directly owned 778,477 shares in the
MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) has received a consensus rating of "Buy" from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and three have given a strong buy rating to the